Laurus Labs Limited
LAURUSLABS
Rangering i aksjer
#1747
Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited,... Established in 2005 and headquartered in Hyderabad, India, Laurus Labs Limited, along with its subsidiaries, operates as a diversified global pharmaceutical company. It focuses on the research, manufacturing, and international distribution of a broad spectrum of medicines and active pharmaceutical ingredients (APIs). The company's API and advanced intermediate offerings cover key therapeutic domains such as anti-retroviral (ARV), antidiabetic, cardiovascular, proton pump inhibitors (PPIs), oncology, gastroenterology, and hepatitis C. Additionally, Laurus Labs develops and produces oral solid dosage forms targeting ARV, antidiabetic, cardiovascular, PPI, and central nervous system (CNS) conditions. Beyond its proprietary products, the firm extends its expertise through contract development and manufacturing services for other pharmaceutical enterprises. It also supplies specialized ingredients vital for nutraceutical, dietary supplement, and cosmeceutical applications. Furthermore, Laurus Labs is at the forefront of innovation, engineering novel enzymatic solutions for industrial biotechnology, and providing animal-origin-free recombinant proteins and enzymes for biopharmaceutical use, alongside offering a range of business support services within the pharmaceutical industry.
Aksjekurs
$22.83
Sist synkronisert: 2026-10-19
Markedsverdi
$12.34B
Endring (1 dag)
0.51%
Endring (1 år)
117.95%
Land
IN
Handel Laurus Labs Limited (LAURUSLABS)
Kategori
Healthcare
P/E-forhold for Laurus Labs Limited (LAURUSLABS)
P/E-forhold per October 2026 TTM: 100.45
Ifølge Laurus Labs Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 100.45. Ved slutten av 2024 hadde selskapet en P/E på 136.45.
P/E-forholdshistorikk for Laurus Labs Limited fra 2013 til 2026
P/E-forhold ved slutten av hvert år
| År | P/E-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 100.45 | 11.37% |
| 2025 | 90.20 | -33.90% |
| 2024 | 136.45 | 584.38% |
| 2023 | 19.94 | -47.92% |
| 2022 | 38.28 | 94.14% |
| 2021 | 19.72 | 45.26% |
| 2020 | 13.57 | -69.76% |
| 2019 | 44.89 | 39.70% |
| 2018 | 32.13 | 30.85% |
| 2017 | 24.56 | -15.80% |
| 2016 | 29.16 | -32.80% |
| 2015 | 43.40 | 43.54% |
| 2014 | 30.23 | -31.70% |
| 2013 | 44.27 | 0.00% |
P/E-forhold for lignende selskaper eller konkurrenter
| Selskap | P/E-forhold | Forskjell i P/E-forhold | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -65.20% |
IN
|
Hvordan lese en P/E-ratio?
Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.
Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.
Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.